• Explore /
  • Poster
  • / Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.

Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.

Abstract Video & Slides Poster

Authors

Mario Lacouture

Mario E. Lacouture

Memorial Sloan Kettering Cancer Center, New York, NY

Mario E. Lacouture , Anisha B Patel , Nicole R. LeBoeuf , Omkar Subhash Marathe , Jonathan Leventhal , Jennifer N. Choi , Elaine Tat Lam , Benjamin S. Kaffenberger , Martin H Voss , Mark L Webb , Robert Claude Tyler , Juegang Ju , Hong Tang , Jie Luo , Milan J. Anadkat , Nicholas J. Vogelzang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care

Clinical Trial Registration Number

NCT04088318

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS396)

DOI

10.1200/JCO.2022.40.6_suppl.TPS396

Abstract #

TPS396

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Anisha B Patel

First Author: Mario E. Lacouture

First Author: Robert E. Martell

First Author: Lorenza Rimassa